Inhibition of Receptor for Advanced Glycation End Products as New Promising Strategy Treatment in Diabetic Retinopathy | Zendy

Mgs. Irsan Saleh | Zendy; Ziske Maritska | Zendy; Nita Parisa | Zendy; Rachmat Hidayat | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Inhibition of Receptor for Advanced Glycation End Products as New Promising Strategy Treatment in Diabetic Retinopathy

Author(s) -

Mgs. Irsan Saleh,

Ziske Maritska,

Nita Parisa,

Rachmat Hidayat

Publication year - 2019

Publication title -

open access macedonian journal of medical sciences

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.288

H-Index - 17

ISSN - 1857-9655

DOI - 10.3889/oamjms.2019.759

Subject(s) - glycation , medicine , rage (emotion) , diabetic retinopathy , vascular endothelial growth factor , endocrinology , retinopathy , glial fibrillary acidic protein , advanced glycation end product , diabetes mellitus , nerve growth factor , receptor , pharmacology , immunohistochemistry , vegf receptors , biology , neuroscience

Extensive intracellular and extracellular formation of advanced glycation end-products (AGEs) is considered a causative factor for vascular injury triggered by hyperglycemia in diabetes. The hyperglycemia will cause accumulation of AGEs, damage to pericytes, nerve growth factor (NGF), glial acid fibrillary protein (GFAP) and increase in vascular endothelial growth factor (VEGF).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research